

Applicants : Bruce D. Gaynor, et al.
Appn. No. : 08/833,838
Filed : April 10, 1997
For : PEPTIDES FOR THE TREATMENT AND DIAGNOSIS OF
SYSTEMIC LUPUS ERYTHEMATOSUS

Page 4

Page 18, line 1, after "DWEYS" insert --(SEQ ID NO:2)--.

Page 18, line 3, after "DWEYS" insert --(SEQ ID NO:2)--.

Page 18, line 5, after "DWEYS peptides" insert --(SEQ ID NO:2)--.

Page 19, line 22, after "Asp-Trp-Asp-Tyr-Ser" insert -- (SEQ ID NO:2)--.

Page 19, line 27, after "DWEYS PEPTIDE" insert --(SEQ ID NO:2)--.

Page 20, line 10, after "DWEYS PEPTIDE" insert --(SEQ ID NO:2)--.

Page 23, replace Table 2 with new Table 2 attached hereto as Appendix C.

Page 24, replace Table 3 with new Table 3 attached hereto as Appendix D.

Please cancel Claims 45-53 without prejudice to Applicants' right to pursue prosecution of these claims in a later-filed continuation or divisional application.

Please add new Claims 54-74 as follows:

54. (new) A method for treating glomerulonephritis mediated by anti-double stranded (ds)-DNA antibodies in a subject in need of such treatment comprising administering to said subject at least one peptide which binds an anti-double stranded DNA antibody in an amount effective to treat glomerulonephritis, wherein said peptide comprises an amino acid sequence of (i) X-Gly-Trp-X-Arg-Val (SEQ ID NO:2), wherein X represents any amino acid known in the art; (ii) X-Trp-X-Tyr-His-X (SEQ ID NO:3), wherein X represents any amino acid known in the art; (iii) X1-Trp-X1-Tyr-X2 (SEQ ID NO:4), wherein X1 represents Asp or Glu, and X2 represents Gly or Ser; or (iv) X1-Gly-X1-Trp-Pro-Arg (SEQ ID NO:5), wherein X1 represents Asp or Glu.

55. (new) The method according to Claim 54 wherein said peptide is 5-30 amino acids in length and comprises X-Gly-Trp-X-Arg-Val (SEQ ID NO:2), wherein X represents any amino acid known in the art.

Applicants : Bruce D. Gaynor, et al.
Appn. No. : 08/833,838
Filed : April 10, 1997
For : PEPTIDES FOR THE TREATMENT AND DIAGNOSIS OF
SYSTEMIC LUPUS ERYTHEMATOSUS

Page 5

56. (new) The method according to Claim 54 wherein said peptide is 5-15 amino acids in length and comprises X-Gly-Trp-X-Arg-Val (SEQ ID NO:2), wherein X represents any amino acid known in the art.

*b5
confidential*
57. (new) The method according to Claim 54 wherein said peptide is 5-10 amino acids in length and comprises X-Gly-Trp-X-Arg-Val (SEQ ID NO:2), wherein X represents any amino acid known in the art.

*sub
c2*
58. (new) The method according to Claim 54 wherein said peptide consists of X-Gly-Trp-X-Arg-Val (SEQ ID NO:2), wherein X represents any amino acid known in the art.

59. (new) The method according to Claim 54 wherein said peptide is 5-30 amino acids in length and comprises X-Trp-X-Tyr-His-X (SEQ ID NO:3), wherein X represents any amino acid known in the art.

60. (new) The method according to Claim 54 wherein said peptide is 5-15 amino acids in length and comprises X-Trp-X-Tyr-His-X (SEQ ID NO:3), wherein X represents any amino acid known in the art.

61. (new) The method according to Claim 54 wherein said peptide is 5-10 amino acids in length and comprises X-Trp-X-Tyr-His-X (SEQ ID NO:3), wherein X represents any amino acid known in the art.

62. (new) The method according to Claim 54 wherein said peptide consists of X-Trp-X-Tyr-His-X (SEQ ID NO:3), wherein X represents any amino acid known in the art.

Applicants : Bruce D. Gaynor, et al.
Appn. No. : 08/833,838
Filed : April 10, 1997
For : PEPTIDES FOR THE TREATMENT AND DIAGNOSIS OF
SYSTEMIC LUPUS ERYTHEMATOSUS

Page 6

63. (new) The method according to Claim 54 wherein said peptide is 5-30 amino acids in length and comprises X1-Trp-X1-Tyr-X2 (SEQ ID NO:4), wherein X1 represents Asp or Glu, and X2 represents Gly or Ser.

64. (new) The method according to Claim 54 wherein said peptide is 5-15 amino acids in length and comprises X1-Trp-X1-Tyr-X2 (SEQ ID NO:4), wherein X1 represents Asp or Glu, and X2 represents Gly or Ser.

65. (new) The method according to Claim 54 wherein said peptide is 5-10 amino acids in length and comprises X1-Trp-X1-Tyr-X2 (SEQ ID NO:4), wherein X1 represents Asp or Glu, and X2 represents Gly or Ser.

66. (new) The method according to Claim 54 wherein said peptide consists of X1-Trp-X1-Tyr-X2 (SEQ ID NO:4), wherein X1 represents Asp or Glu, and X2 represents Gly or Ser.

67. (new) The method according to Claim 54 wherein said peptide is 5-30 amino acids in length and comprises X1-Gly-X1-Trp-Pro-Arg (SEQ ID NO:5), wherein X1 represents Asp or Glu.

68. (new) The method according to Claim 54 wherein said peptide is 5-15 amino acids in length and comprises X1-Gly-X1-Trp-Pro-Arg (SEQ ID NO:5), wherein X1 represents Asp or Glu.

69. (new) The method according to Claim 54 wherein said peptide is 5-10 amino acids in length and comprises X1-Gly-X1-Trp-Pro-Arg (SEQ ID NO:5), wherein X1 represents Asp or Glu.